ArticleMolecular cancer therapeutics2020
Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Volatilomic Signatures of Parental and Oxaliplatin-Resistant HCT116 Colon Cancer Cell Lines.International journal of molecular sciences · 2026Article
- Dual-Action NSAID-Gold(I) Alkynyl Hybrids for Synergistic Anti-Inflammatory and Anticancer Therapy of Colorectal Cancer.Inorganic chemistry · 2026Article
- NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer.World journal of gastroenterology · 2025Article
- Review
- The unique Pt(II)-induced nucleolar stress response and its deviation from DNA damage response pathways.The Journal of biological chemistry · 2024Article
- Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies.Frontiers in pharmacology · 2023Review
- Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?Clinical and translational science · 2022Review
- Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.Pharmaceuticals (Basel, Switzerland) · 2022Review
- GlutathioneFrontiers in oncology · 2022Article
- Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients.BMC veterinary research · 2021Article
- Applications of Adductomics in Chemically Induced Adverse Outcomes and Major Emphasis on DNA Adductomics: A Pathbreaking Tool in Biomedical Research.International journal of molecular sciences · 2021Review
- Preclinical Models for Bladder Cancer Research.Hematology/oncology clinics of North America · 2021Review
- The DNA damage response network in the treatment of head and neck squamous cell carcinoma.ESMO open · 2021Article
- Article
- Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cells.International journal of biological sciences · 2021Article
- Phase 0/microdosing approaches: time for mainstream application in drug development?Nature reviews. Drug discovery · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Maike ZimmermannDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Tao LiDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Thomas J SemradDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.ORCID 0000-0002-7810-5887
Chun-Yi WuDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, California.
Aiming YuDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, California.
George CiminoAccelerated Medical Diagnostics Incorporated, Berkeley, California.
Michael MalfattiLawrence Livermore National Laboratory, Livermore, California.
Kurt HaackLawrence Livermore National Laboratory, Livermore, California.
Kenneth W TurteltaubLawrence Livermore National Laboratory, Livermore, California.
Chong-Xian PanDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.
May ChoDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Edward J KimDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.ORCID 0000-0002-8660-7465
Paul T HendersonDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California. phenderson@ucdavis.edu.ORCID 0000-0003-4238-0446
University of California Davis Medical Center · USExcel Diagnostics Imaging · USLawrence Livermore National Laboratory · USTahoe Forest Hospital · USVA Northern California Health Care System · US
Funding
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9MVITAMIN C (ASCORBATE) METABOLISM IN DROSPHILA MELANOGASTERP41RR013461 · NCRR · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI LAM, KIT S · 1999 to 2011
$20.8MResource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)P41GM103483 · NIGMS · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI TURTELTAUB, KENNETH W. · 2012 to 2019
$12.0MUC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4MUniversity of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health DisparitiesU54CA233306 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARVAJAL CARMONA, LUIS GUILLERMO, CHEN, MOON SHAO-CHUANG · 2018 to 2022
$6.8MFeasibility of predicting AML response to induction chemotherapyR43CA221473 · NCI · ACCELERATED MEDICAL DIAGNOSTICS, LLC · PI HENDERSON, PAUL THOMAS · 2017 to 2017
$300kPotentiation of Immunotherapy with targeted nanoporphyrin in bladder cancerI01BX003840 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2018 to 2021
–Development of targeting nanotherapeutics against bladder cancerI01BX001784 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2014 to 2017
–BLRD VA I01 BX001784BLRD VA I01 BX003840NCI NIH HHS HHSN261201000133CNCI NIH HHS HHSN261201200048CNCI NIH HHS K12 CA138464NCI NIH HHS P30 CA093373NCI NIH HHS R43 CA221473NCI NIH HHS U54 CA233306NCRR NIH HHS P41 RR013461NIGMS NIH HHS P41 GM103483
Abstract
FOLFOX is one of the most effective treatments for advanced colorectal cancer. However, cumulative oxaliplatin neurotoxicity often results in halting the therapy. Oxaliplatin functions predominantly via the formation of toxic covalent drug-DNA adducts. We hypothesize that oxaliplatin-DNA adduct levels formed
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsApoptosisBiomarkers, TumorCarbon RadioisotopesCell ProliferationColorectal NeoplasmsDNA AdductsDose-Response Relationship, DrugFluorouracilHumansLeucovorinLeukocytes, MononuclearLiver NeoplasmsOxaliplatinPatient SelectionPilot ProjectsBiomarkers, TumorCarbon RadioisotopesDNA AdductsFluorouracilLeucovorinOxaliplatin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.